News | August 05, 2021
Dr. Reddy's Laboratories signs asset purchase agreement with BioDelivery Sciences
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
Dr.Reddy's will receive U.S. $6 million upfront upon closing followed by U.S. $9 million one year from closing
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.16.18 crores for the period ended June 30, 2020.
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
SteriScience will infuse an additional amount of Rs. 74.5 crore, making a total investment commitment of Rs. 114.5 crore in BSL
The company has already embarked upon significant expansion in Turkey
The company has a cumulative total of 147 ANDA approvals (129 final approvals and 18 tentative approvals) from USFDA
Ranitidine Hydrochloride is an important product for Solara and is manufactured at its Cuddalore site
2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy's
Subscribe To Our Newsletter & Stay Updated
